Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
Charlotte-Paige RolleMezgebe BerheTulika SinghRoberto OrtizAnson WurapaMoti RamgopalDushyantha T JayaweeraPeter A LeoneJessica E MatthewsMichael CupoMark R UnderwoodKonstantinos AngelisBrian R WynneDeanna MerrillChristopher NguyenJean van WykAndrew R ZolopaPublished in: Open forum infectious diseases (2023)
Results demonstrated high proportions of participants with sustained virologic suppression, no treatment-emergent resistance, and good safety over 48 weeks, supporting first-line use of DTG/3TC in a test-and-treat setting.